Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

This process entails comprehensive molecular simulations of the target protein, individually and in complex with essential partner proteins, along with ensemble virtual screening that focuses on conformational mobility in both its free and complex states. Potential binding pockets are considered at the protein-protein interaction interface and in remote allosteric locations to address every conceivable mechanism of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P01730

UPID:
CD4_HUMAN

ALTERNATIVE NAMES:
T-cell surface antigen T4/Leu-3

ALTERNATIVE UPACC:
P01730; B2R737; D3DUS5; Q4ZGK2; Q5U066; Q9UDE5

BACKGROUND:
Integral to the immune response, T-cell surface glycoprotein CD4 plays multiple roles in defending the body against pathogens. It acts as a coreceptor in T-cells for MHC class II molecule:peptide complexes, initiating intracellular signaling pathways that lead to T-helper cell activation. Beyond T-cells, CD4 influences macrophage differentiation and cytokine expression, showcasing its versatility in immune function.

THERAPEUTIC SIGNIFICANCE:
The association of CD4 with Immunodeficiency 79, characterized by severe immune response failure to HPV, highlights its therapeutic potential. Targeting CD4 pathways could offer new avenues for treating immune deficiencies and combating viral diseases, including HIV-1, by bolstering the body's natural defense mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.